- 1 Plasma markers of neurologic injury and systemic inflammation in individuals with self-
- 2 reported neurologic post-acute sequelae of SARS-CoV-2 infection (PASC)
- 3 Michael J. Peluso, MD, ¹[^] Hannah M. Sans, MPH, ¹* Carrie A. Forman, BA, ¹* Alyssa N. Nylander, MD,
- 4 PhD,² Hsi-en Ho, MD,³ Scott Lu, MBBS,⁴ Sarah A. Goldberg, BS,⁴ Rebecca Hoh, MS, RD,¹ Viva Tai,
- 5 MPH, RD,¹ Sadie E. Munter, BA,⁵ Ahmed Chenna, PhD,⁶ Brandon C. Yee, BS,⁶ John W. Winslow,
- 6 PhD,⁶ Christos J. Petropoulos, PhD,⁶ Jeffrey N. Martin, MD,⁴ J. Daniel Kelly, MD, PhD,⁴ Matthew S.
- 7 Durstenfeld, MD⁷ Priscilla Y. Hsue, MD,⁷ Peter W. Hunt, MD,⁵ Meredith Greene, MD,⁸ Felicia C.
- 8 Chow, MD, 9 Joanna Hellmuth, MD, 10 Timothy J. Henrich, MD, 5 David V. Glidden, PhD, 4 Steven G.
- 9 Deeks, MD¹
- ¹ Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco,
- 12 CA, USA

- ² Department of Neurology, University of California, San Francisco, CA, USA
- ³ Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ⁴ Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
- ⁵ Division of Experimental Medicine, University of California, San Francisco, CA, USA
- ⁶ Monogram Biosciences Inc., South San Francisco, CA, USA
- ⁷ Division of Cardiology, University of California, San Francisco, CA, USA
- ⁸ Division of Geriatrics, University of California, San Francisco, CA, USA
- ⁹ Weill Institute for Neurosciences, Departments of Neurology and Medicine (Infectious Diseases),
- 21 University of California, San Francisco, CA, USA
- ¹⁰ Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University
- of California, San Francisco, CA, USA
- 25 * Contributed equally

24

^To whom correspondence should be addressed: Michael J. Peluso, MD
995 Potrero Ave.
San Francisco, CA 94110
michael.peluso@ucsf.edu

Keywords: COVID-19, SARS-CoV-2, post-acute sequelae of SARS-CoV-2 infection (PASC),
neurofilament light chain, glial fibrillary acidic protein

Short Title: Markers of neurologic injury in post-acute COVID-19

Stats: Abstract = 347 words, Text = 2996 words, References = 63, Tables = 1, Figures = 1,
Supplemental Tables = 8

Key Points (100 words)

11

16

17

19

50

- 12 Question: Do individuals with and without self-reported neurologic symptoms following SARS-CoV-2
- infection have different levels of biomarkers of neurologic injury or immune activation?
- 14 Findings: In this cohort study of 121 adults, individuals reporting neurologic symptoms beyond 90
- days following SARS-CoV-2 infection had higher levels of glial fibrillary acidic protein but not
 - neurofilament light chain. Levels of several markers of inflammation including interleukin-6, tumor
 - necrosis factor-alpha, and monocyte chemoattractant protein-1 were also elevated.
- 18 Meaning: Post-acute neurologic symptoms following SARS-CoV-2 infection are associated with
 - significant differences in levels of certain biomarkers. Further investigation may provide clues to the
 - biologic pathways underlying these symptoms.

ABSTRACT

⁷4

Background: The biologic mechanisms underlying neurologic post-acute-sequelae of SARS-CoV-2

infection (PASC) are incompletely understood.

Methods: We measured markers of neuronal injury (glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL]) and soluble markers of inflammation among a cohort of people with prior confirmed SARS-CoV-2 infection at early and late recovery following the initial illness (defined as less than and greater than 90 days, respectively). The primary clinical outcome was the presence of self-reported central nervous system (CNS) PASC symptoms during the late recovery timepoint. We compared fold-changes in marker values between those with and without CNS PASC symptoms using linear mixed effects models and examined relationships between neurologic and immunologic markers using rank linear correlations.

Results: Of 121 individuals, 52 reported CNS PASC symptoms. During early recovery, those who went on to report CNS PASC symptoms had elevations in GFAP (1.3-fold higher mean ratio, 95% CI 1.04-1.63, p=0.02), but not NfL (1.06-fold higher mean ratio, 95% CI 0.89-1.26, p=0.54). During late recovery, neither GFAP nor NfL levels were elevated among those with CNS PASC symptoms. Although absolute levels of NfL did not differ, those who reported CNS PASC symptoms demonstrated a stronger downward trend over time in comparison to those who did not report CNS PASC symptoms (p=0.041). Those who went on to report CNS PASC also exhibited elevations in IL-6 (48% higher during early recovery and 38% higher during late recovery), MCP-1 (19% higher during late recovery). GFAP and NfL correlated with levels of several immune activation markers during early recovery; these correlations were attenuated during late recovery.

Conclusions: Self-reported neurologic symptoms present >90 days following SARS-CoV-2 infection are associated with elevations in markers of neurologic injury and inflammation at early recovery timepoints, suggesting that early injury can result in long-term disease. The correlation of GFAP and NfL with markers of systemic immune activation suggests one possible mechanism that might contribute to these symptoms. Additional work is needed to better characterize these processes and to identify interventions to prevent or treat this condition.

BACKGROUND

32

33

34

35

36

37

38

39

90

31

)2

93

)4

35

96

37

98

99

)(

)1

)2

)3

)4

)5

There is an urgent need to understand the pathophysiology that underlies the post-acute sequelae of SARS-CoV-2 infection (PASC), a condition characterized by persistent symptoms in some individuals recovering from coronavirus disease 2019 (COVID-19). While a spectrum of symptoms is reported among individuals experiencing PASC, neurologic symptoms are particularly common. 1-5 Limited data are available on the biologic predictors and correlates of these symptoms. Neurologic involvement during COVID-19 is common.⁶⁻⁸ Acute illness is associated with substantial immune activation⁹⁻¹¹ and central nervous system (CNS) dysfunction. 11-16 A handful of studies have measured serum glial fibrillary acidic protein (GFAP), an intermediate filament protein found in the cytoskeleton of CNS astrocytes. 17 and neurofilament light chain (NfL), a cytoskeletal protein expressed in the axons of neurons¹⁸ during acute COVID-19. 19-28 In some cases, higher levels of these markers were identified in patients with neurologic symptoms during acute infection: 21-25 other studies have not identified such relationships.^{27,28} These markers could be of prognostic value in acute COVID-19. 23,24,29-31 A high proportion of individuals experience ongoing physical or mental health symptoms in the 2-12 months following COVID-19.³²⁻³⁷ Recent work has suggested that immune activation might play a role in PASC. 13,38 Inflammatory markers such as interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, and interferon-gamma induced protein (IP)-10 have been associated with ongoing symptoms.³⁸ These markers, particularly IL-6, may correlate with long-term neuropsychiatric manifestations of COVID-19.14 However, there are limited data on the relationship between biomarkers of inflammation, neurologic injury, and neurologic symptoms during the post-acute period. 25,39,40 In a prior analysis utilizing a broad case definition of PASC (i.e., presence of any 1 of 32 COVID-19attributed symptoms), we found that differences in levels of inflammatory markers predicted the presence of symptoms >90 days following COVID-19.38 In the current report, we investigated a more

specific outcome defined by 5 self-reported neurologic symptoms. We evaluated markers of CNS injury and systemic inflammation among those with and without this more specific phenotype. A better understanding of the relationships between these markers among individuals with neurologic manifestations of PASC could help in identifying therapies to prevent and/or manage this condition as the pandemic continues.

METHODS

)6

)7

)8

)9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Participants and procedures

Beginning in April 2020 we conducted a prospective longitudinal study of individuals who had recently

recovered from confirmed SARS-CoV-2 infection (Long-term Impact of Infection with Novel

Coronavirus (LIINC) cohort; NCT04362150).41 The vast majority (78%) had not been hospitalized

during the acute phase. The determination of eligibility was agnostic to the presence or absence of

persistent SARS-CoV-2 attributed symptoms.

A research coordinator administered a study questionnaire at early (=<90 days) and late (>90 days)

recovery time points following COVID-19 symptom onset. Participants were gueried regarding the

presence of 32 symptoms, including 8 neurologic symptoms (Supplemental Table 1). A symptom was

recorded as present if it was reported at the time of the visit and was either new in onset since the

time of SARS-CoV-2 infection or had worsened since the time of SARS-CoV-2 infection. Symptoms

that preceded and were unchanged following SARS-CoV-2 infection were recorded as absent. We

also collected information about demographics and medical history, and retrospectively collected

information on symptoms experienced during the acute phase of the illness. Blood was collected by

venipuncture at each visit.

Clinical outcomes

The primary clinical outcome was central nervous system (CNS) PASC, defined as the presence of at least one CNS symptom at a late recovery visit occurring >90 days from initial COVID-19 symptom onset. These symptoms included: memory/concentration issues, headache, vision problems, dizziness, and balance issues. We selected these symptoms because they were felt to best reflect dysfunction of the central nervous system and most likely to associate with biologic processes that could be identified using the two primary biomarker outcomes. A secondary analysis examined any neurological symptom, which included the following in addition to the central neurological symptoms: problems with smell or taste, smelling an odor that is not really present, and numbness/tingling (Supplemental Table 2).

Biomarker assays

Plasma biomarker measurements were performed using the fully automated HD-X Simoa platform at two timepoints: early recovery (median 52 days) and late recovery (median 123 days). Those performing the assays were blinded to clinical information. The primary analytes were plasma GFAP and NfL measured using the GFAP Discovery and NF-light Advantage kit assays, respectively (Quanterix). We also measured levels of markers that have been found to be important during acute SARS-CoV-2 infection^{10,11} using multiplex (Cytokine 3-PlexA: IL-6, IL-10, TNF-alpha) or single-plex (IFNy, IP-10, MCP-1) kits. SARS-CoV-2 receptor binding domain (RBD) IgG was also assayed. All assays were performed according to the manufacturer's instructions and assay performance was consistent with the manufacturer's specifications.

Statistical analysis

We log-transformed all biomarkers to reduce influence of outliers and to permit interpretation of fold-changes. As in prior work,³⁸ we compared the ratio of the mean transformed values for each biomarker between those with and without persistent neurologic symptoms using linear mixed effects models with terms for PASC, time period (early versus late recovery), and their interaction. This

approach permits comparison of the values at early and late time points as well as assessment of whether trajectories in marker values differ between those with and without persistent symptoms. We calculated fold-changes and 95% confidence intervals by exponentiating the coefficients to give the ratio between the untransformed biomarker values. We used Spearman correlations to evaluate relationships between levels of neurologic and immune markers. All p-values are two-sided. We used Stata (version 16.1; StataCorp, College Station, TX) and Prism (version 9.1.2, GraphPad Software, L.L.C., San Diego, CA).

Ethics

- All participants provided written informed consent. The study was approved by the Institutional
 - Review Board at the University of California, San Francisco.

RESULTS

35 Study participants

The study included 121 individuals with primary outcome data (Table 1), 92 of whom (76%) had a paired early recovery sample for analysis. During acute COVID-19, the majority (89, 74%) had been symptomatic outpatients, while 27 (22%) had been hospitalized. Five (4%) reported asymptomatic SARS-CoV-2 infection. Of those hospitalized, 23 (85%) required supplemental oxygen and 3 (11%) required mechanical ventilation. SARS-CoV-2-targeted treatment was uncommon: 4 individuals (15%) received remdesivir, 1 (4%) received convalescent plasma, and 5 (19%) received steroids. No hospitalized participant was known to have experienced an acute neurological event during their hospitalization. All samples were collected prior to the availability of SARS-CoV-2 vaccination.

Fifty-two individuals, of whom the majority were women, reported CNS symptoms at the late recovery timepoint (Table 1). Among them, the most commonly reported CNS symptoms were trouble concentrating (81%) headache (35%) and dizziness (35%).

Early recovery visits took place at a median of 52 (IQR 38-64) days post-infection. Late recovery visits took place at a median of 123 (IQR 114-135) days post-infection. The early recovery visit for those reporting CNS PASC symptoms occurred slightly later than for those who denied CNS PASC symptoms (60 [IQR 40-67] and 49 [IQR 37-59] days, respectively). The timing of the late recovery visit was similar between those with and without CNS PASC (123 [IQR 117-137] and 124 [IQR 113-134] days, respectively).

Levels of biomarkers among those with and without CNS PASC symptoms

)1

}2

)4

)5

)7

We first compared levels of each marker measured during early recovery between those who went on to report CNS PASC symptoms and those who did not (Figure 1, Supplemental Table 3). At the early recovery timepoint, those who went on to report CNS PASC had significantly higher levels of GFAP (1.3-fold higher mean ratio, 95% CI 1.04-1.63, p=0.02), but not NfL (1.06-fold higher mean ratio, 95% CI 0.89-1.26, p=0.54). Those who went on to report CNS PASC also had higher levels of IL-6 (1.48-fold higher mean ratio, 95% CI 1.12-1.96, p=0.006), MCP-1 (1.19-fold higher mean ratio, 95% CI 1.01-1.40, p=0.034), and TNF-alpha (1.19-fold higher mean ratio, 95% CI 1.06-1.34, p=0.003) compared to those who did not report CNS PASC. Trends for other markers were in a similar direction, although the differences did not achieve statistical significance.

We next compared levels of each biomarker measured during late recovery between those with and without self-reported CNS PASC at this visit (Figure 1, Supplemental Table 3). No significant differences were detected in GFAP or NfL between those with and without PASC (Figure 1). Those reporting persistent CNS PASC symptoms had persistent elevations in IL-6 (1.38-fold higher mean ratio, 95% CI 1.07-1.77, p=0.013), and TNF-alpha (1.13-fold higher mean ratio, 95% CI 1.02-1.26,

- p=0.022). Interferon-gamma was lower (0.71-fold difference, 95% CI 0.55-0.91, p=0.007). Levels of
- 39 SARS-CoV-2 RBD IgG did not differ between groups at either the early or late timepoints.
- 00 Changes in levels of biomarkers over time
- To examine changes in the levels of these markers between the early and late recovery timepoints,
- we used mixed models to indicate changes over time among those with and without CNS PASC
- symptoms (Figure 1, Supplemental Table 3). Significant differences in trends of NFL (p=0.041), MCP-
- 1 (p=0.019), and IFN-gamma (p=0.012) were noted between the CNS PASC and non-CNS PASC
 - groups. As predicted from the cross-sectional analyses, consistently higher levels of IL-6 and TNF-
 - alpha were observed, although the trends in the levels of these markers did not differ between
-)7 groups.

)5

)6

10

11

19

- No Relationships between neurologic and inflammatory markers
- 19 To examine relationships between the neurological markers and markers of inflammation, we
 - performed nonparametric pairwise analyses at early and late recovery timepoints (Figure 2). GFAP
 - levels weakly correlated with MCP-1 (r=0.21, p=0.02) and IL-6 (r=0.18, p=0.054) at the early
- timepoint and with IL-6 at the late timepoint (r=0.19, p=0.043). NfL correlated with MCP-1 (r=0.41,
- 13 p<0.001), IL-6 (r=0.23, p=0.012), IFN-gamma (r=0.28, p=0.003), and TNF-alpha (r=0.32, p<0.001) at
- the early timepoint and with MCP-1 (r=0.31, p<0.001) at the late timepoint. In addition, there was a
- strong correlation between NfL and SARS-CoV-2 IgG at the early timepoint (r=0.40, p<0.001).
- 16 Influence of symptoms during acute infection
- We did not identify significant differences in levels of markers at either recovery timepoint between
- those with and without prior CNS symptoms during acute infection (Supplemental Table 4). For some
 - markers, we noted non-significant trends toward differential changes over time in groups with and
- without CNS symptoms during acute infection. These included NfL (more steep decline among those

with acute CNS symptoms, p=0.066) and anti-RBD IgG (less steep decline among those with acute

CNS symptoms, p=0.063).

Sensitivity analyses

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

10

11

12

13

Because of the relationship between age and levels of NfL, 42 we performed an age-adjusted analysis

which did not change the primary results (no new relationship between NfL and PASC was identified

(Supplemental Table 5). We also repeated the primary analysis adjusting for age, sex, and prior

hospitalization status which did not change the interpretation of the results (Supplemental Table 6),

although some of the relationships were slightly attenuated.

We performed a secondary analysis in which individuals reporting any symptom that could be

attributed to a primary neurologic cause (including the peripheral nervous system) were compared

against individuals reporting no neurologic symptoms (Supplemental Table 7). In this analysis, the

elevation in GFAP seen at early follow-up among those reporting any neurologic PASC symptom was

slightly attenuated (mean ratio 1.24, 95% CI 1.00-1.55, p=0.052). Similar elevations were seen in IL-

6, MCP-1, and TNF-alpha at early follow-up among those reporting any neurologic PASC symptom.

At late follow-up, those with any neurologic PASC had higher levels of IL-6, and TNF-alpha. The

difference in interferon-gamma seen among those with CNS PASC in the primary analysis was no

longer statistically significant.

Finally, because we have previously found that PASC is associated with elevations in certain

markers, we performed an analysis comparing those with CNS PASC to those reporting no symptoms

of any kind during late recovery (Supplemental Table 8). The interpretation of the primary results was

again unchanged, although some of the findings were attenuated.

DISCUSSION

15

16

17

18

19

50

51

52

53

54

55

56

57

58

59

30

31

32

33

34

35

36

37

A large proportion of individuals with PASC experience symptoms that may be attributed to nervous system dysfunction, 1-5 but the pathophysiologic processes underlying such symptoms remain poorly understood. We investigated associations between self-reported neurologic symptoms and plasma biomarkers of CNS injury and systemic inflammation during early and late recovery periods following laboratory-confirmed SARS-CoV-2 infection. Those reporting CNS PASC symptoms approximately four months following initial infection had earlier elevations in several biomarkers, including GFAP, IL-6, and TNF-alpha suggesting that the acute infection resulted in direct CNS tissue injury and systemic inflammation, both of which might be causally related to the development of CNS PASC. Replication of these findings in larger and more diverse cohorts may be a first step toward identifying interventions for their prevention and/or management. Elevations in GFAP during early recovery were associated with later CNS PASC. While we did not observe elevations in NfL at either timepoint, we did identify a more precipitous decline among those reporting CNS PASC. Together, these observations lend support to the possibility of early injury that resolves while clinical symptoms persist. Our findings are in line with studies that identified a correlation between NfL and/or GFAP with neurologic symptoms during the acute phase, but found no association between the biomarker levels and persistence of neurologic symptoms after six months.^{39,40} Further work exploring the dynamics of these markers in cohorts with measurements performed during the period of acute illness, as well as efforts to identify downstream markers which may persist during later recovery, will be informative. This analysis builds upon several observations we and others have made suggesting that markers of systemic inflammation may be important in driving PASC. 13,38 While we previously observed associations between such markers and broadly defined PASC (i.e., any 1 of 32 COVID-19-attributed symptoms),³⁸ it is notable that the strength of these associations was more pronounced in the current analysis utilizing a more specific PASC outcome (i.e., any 1 of 5 CNS PASC symptoms). At the same

39

70

71

72

73

74

75

76

77

78

79

30

31

32

33

34

35

36

37

38

39

90

31

time, the fact that those reporting CNS PASC symptoms had a greater number of PASC symptoms overall makes it challenging to disentangle a more specific CNS PASC phenotype from more severe PASC in general. It suggests that CNS PASC might reflect one extreme on a spectrum of illness. Further work to compare those with distinct phenotypic clusters of symptoms, if they exist, could further elucidate the biology. Dysregulation of IL-6 and TNF-alpha is potentially deleterious in inflammatory disease states, 43,44 related to systemic and localized tissue inflammation and endothelial dysfunction. The reason for elevations in levels of these markers among those with CNS PASC is not clear. One possibility is that they represent residual inflammation from acute infection that is slower to resolve among those with PASC. However, the identification of persistent differences months following infection suggests other possibilities such as a delayed return to immunologic homeostasis related to ongoing stimulation.45 dysfunction, 46-48 antigenic microvascular pathophysiology (e.g., persistent autoimmunity. 49 etc.). While the source of these inflammatory markers is unknown, both IL-6 and TNF-alpha can be produced by CNS as well as peripheral immune cells and both cytokines have been implicated in CNS pathology. 50,51 Similarly, MCP-1 is a chemokine expressed by macrophages and microglia, and elevations have been implicated in neurocognitive conditions. 52,53 Further investigation into the source of IL-6, TNF-alpha, and MCP-1 among those with CNS PASC, which may include co-investigation of the peripheral blood and CSF compartment, will be needed to provide clues to the pathophysiology underlying this condition. Interestingly, levels of these biomarkers during early and late recovery did not differ between those with and without self-reported neurologic symptoms during acute infection. This suggests that residual neurologic injury in those with neuro-symptomatic acute COVID-19, at least among study populations comprised primarily of outpatients, is not the most important causal factor. The determination of who will have ongoing elevations in markers of neurologic injury and/or who will go

on to experience CNS PASC during late recovery appears to be more complex than identifying those who report neurologic symptoms during the acute phase of illness.

32

93

)4

35

96

)7

98

99

00

)1

)2

)3

)4

)5

)6

)7

)8

)9

10

11

12

13

14

15

While the pathogenesis of neurologic complications from SARS-CoV-2 is yet unclear, several hypotheses have been proposed. These include direct viral infection, systemic inflammation, compartmentalized neuroinflammation, and sequelae of thrombotic injury. Viral tropism for human astrocytes has been demonstrated in-vivo,⁵⁴ post-mortem brain samples from COVID-19 patients have shown preferential infection of astrocytes,⁵⁵ and a case-control study of brain samples uncovered altered gene expression in some astrocytes.⁵⁶ Astrocyte dysfunction could relate to emerging cognitive PASC complaints, which can encapsulate attention and working memory deficits.⁵⁷ Direct invasion of neurons has been suggested based on their expression of ACE-2 receptor, but SARS-Cov-2 viral particles have been only rarely demonstrated in neuropathological autopsy studies and studies of CSF during acute infection.^{58–60} Additionally, there is evidence of multifocal inflammatory infiltrates consisting of lymphocytes as well as activated innate immune cells in autopsy tissue.⁶¹ Further investigation of PASC will require in-depth exploration of what is occurring in the CNS compartment during both acute and recovery time periods.

Our analysis has several important limitations. First, while recruitment was agnostic to the presence of persistent symptoms, the cohort is not representative of the general population with PASC. Second, we relied on self-report to ascertain the presence of symptoms. This risks misattribution of symptoms to neurologic causes and therefore misclassification of individuals as having CNS PASC. In addition, it is difficult to disentangle neurologic symptoms from non-neurologic symptoms which might co-occur and it is possible that differences are driven by more severe PASC in general rather than neurologic symptoms specifically. Affective symptoms may also co-occur and be inter-related. Third, we did not include any objective neurologic measurements, and studies that do include such measurements (which may include detailed neurological history and examination, neurocognitive and

neuropsychiatric testing, and/or neuroimaging) are likely to be more informative. Fourth, we measured a limited set of biomarkers. Our measurements were all taken in blood, and while there are established relationships between blood and CSF measurements in other disease conditions, 62,63 these have yet to be established for COVID-19.28 For this reason, more detailed studies that include CSF analyses will be critical. Finally, paired pre-pandemic specimens were not available, and it is possible that elevations in these markers among those with CNS PASC preceded SARS-CoV-2 infection. Regardless, we believe that the observations made here provide important clues to important biological pathways to inform more detailed neurological evaluations and potential therapeutic studies.

FIGURE CAPTIONS

Figure 1. Cross-sectional measurements and longitudinal trends in biomarker levels among those with and without CNS PASC. P-values reflect group comparisons during early and late recovery, as well as comparison of change over time between groups. GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor alpha; IL-10, interleukin-10; IFN-gamma, interferon-gamma; MCP-1, monocyte chemoattractant protein 1; IP-10, interferon-gamma induced protein 10; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IgG, immunoglobulin G. Early recovery represents a median of 52 days post-SARS-CoV-2 symptom onset (or positive PCR); late recovery represents a median of 123 days post-SARS-COV-2 symptom onset (or positive PCR).

Figure 2. Relationships between biomarkers of neurologic injury and systemic inflammation in the full cohort. Data reflect non-parametric correlations between markers at early and late recovery timepoints. GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor alpha; IL-10, interleukin-10; IFN-gamma, interferon-gamma; MCP-1,

monocyte chemoattractant protein 1; IP-10, interferon-gamma induced protein 10; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IgG, immunoglobulin G. Early recovery represents a median of 52 days post-SARS-CoV-2 symptom onset (or positive PCR); late recovery represents a median of 123 days post-SARS-COV-2 symptom onset (or positive PCR).

FOOTNOTES

Acknowledgements

We are grateful to the LIINC study participants and to the clinical staff who provided care to these individuals during their acute illness period and during their recovery. We thank Dr. Isabel Rodriguez-Barraquer, Dr. Bryan Greenhouse, and Dr. Rachel Rutishauser for their contributions to the LIINC leadership team. We acknowledge current and former LIINC clinical study team members Tamara Abualhsan, Andrea Alvarez, Mireya Arreguin, Melissa Buitrago, Monika Deswal, Emily Fehrman, Heather Hartig, Yanel Hernandez, Marian Kerbleski, James Lombardo, Enrique Martinez, Lynn Ngo, Dylan Ryder, Ruth Diaz Sanchez, Cassandra Thanh, Fatima Ticas, Leonel Torres, and Meghann Williams; and LIINC laboratory team members Amanda Buck, Tyler-Marie Deveau, Joanna Donatelli, Jill Hakim, Nikita Iyer, Owen Janson, Christopher Nixon, Isaac Thomas, and Keirstinne Turcios. We thank Elnaz Eilkhani for coordination with the Institutional Review Board. We acknowledge the contributions of the UCSF Clinical and Translational Science Unit, Core Immunology Laboratory, and AIDS Specimen Bank. We thank Jeremy Lambert from Quanterix for his advice and assistance with the SARS-CoV-2 IgG antibody assay kits.

Author Contributions

MJP, HH, JNM, JDK, MG, FCC, JH, TJH, and SGD designed the study, which was supported through funding to MJP, JDK, TJH, and SGD. MJP, ANN, RH, VT, and JDK collected clinical data and biospecimens, which were processed by SEM in the laboratory of TJH. Specimens were analyzed by

- 36 AC, BCY, JWW, and CJP. MJP, SL, SAG, and DVG performed and/or interpreted the statistical
- 37 analyses. MJP, HMS, CAF, ANN, HH, JNM, DVG, and SGD drafted the initial manuscript with input
- from JDK, AC, BCY, JWW, CJP, PWH, MSD, PYH, MG, TJH, FCC, and JH. All authors edited,
- reviewed, and approved the final manuscript.

Funding

70

75

78

31

32 33

34

35

36

37

38

- 71 This work was supported by the National Institute of Allergy and Infectious Diseases (NIH/NIAID
- ⁷² 3R01Al141003-03S1 [to TJ Henrich] and by the Zuckerberg San Francisco Hospital Department of
- 73 Medicine and Division of HIV, Infectious Diseases, and Global Medicine. MJP is supported on NIH
- ⁷⁴ T32 Al60530-12 and by the UCSF Resource Allocation Program.

Conflicts of Interest

- 76 AC, BCY, JWW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCorp.
- 77 DVG reports grants and/or personal fees from Merck and Co. and Gilead Biosciences outside the
 - submitted work. SGD reports grants and/or personal fees from Gilead Sciences, Merck & Co., Viiv,
- 79 AbbVie, Eli Lilly, ByroLogyx, and Enochian Biosciences outside the submitted work. TJH reports
- 30 grants from Merck and Co., Gilead Biosciences, and Bristol-Myers Squibb outside the submitted
 - work. The remaining authors report no conflicts.

REFERENCES

- 1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med.* 2021;27(4):601-615.
- 2. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis. doi:10.21203/rs.3.rs-266574/v1
- 3. Ayoubkhani D, Pawelek P, Gaughan C. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK Office for National Statistics. Published September 15, 2021. Accessed September 20, 2021.
- https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddisea
- 33 ses/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeople
- 34 withcoronaviruscovid19intheuk/26april2020to1august2021

- Blomberg B, Mohn KG-I, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. *Nat Med.* Published online June 23, 2021. doi:10.1038/s41591-021-01433-3
- 5. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19.

 Nature. 2021;594(7862):259-264.
- 6. Chou SH-Y, Beghi E, Helbok R, et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. *JAMA Netw Open.* 2021;4(5):e2112131.
- 7. Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. *Acta Neurol Scand*. 2020;142(1):14-22.
- 8. Leven Y, Bösel J. Neurological manifestations of COVID-19 an approach to categories of pathology. *Neurol Res Pract.* 2021;3(1):39.
- 9. Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. *Front Pediatr.* 2020;8:607647.
- 10. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature*. 2020;584(7821):463-469.
- 11. Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med.* 2020;26(10):1636-1643.
- 12. Espíndola OM, Gomes YCP, Brandão CO, et al. Inflammatory Cytokine Patterns Associated with Neurological Diseases in Coronavirus Disease 2019. *Ann Neurol*. 2021;89(5):1041-1045.
- 13. Ong SWX, Fong S-W, Young BE, et al. Persistent Symptoms and Association With Inflammatory
 Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. *Open Forum Infectious Diseases*. 2021;8(6). doi:10.1093/ofid/ofab156
- 14. Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. *Psychoneuroendocrinology*. 2021;131:105295.
- 15. Merza MY, Hwaiz RA, Hamad BK, Mohammad KA, Hama HA, Karim AY. Analysis of cytokines in
 SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan Region of Iraq. *PLoS One*.
 2021;16(4):e0250330.
- 16. Ahearn ☐ Ford S, Lunjani N, McSharry B, et al. Long ☐ term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS ☐ CoV ☐ 2 infection. *Allergy*. doi:10.1111/all.14953
- 17. McMahon PJ, Panczykowski DM, Yue JK, et al. Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. *J Neurotrauma*. 2015;32(8):527-533.
- 18. Barro C, Chitnis T, Weiner HL. Blood neurofilament light: a critical review of its application to neurologic disease. *Ann Clin Transl Neurol*. 2020;7(12):2508-2523.
- 31 19. AAAS. Accessed September 10, 2021. https://stm.sciencemag.org/content/13/602/eabi7643/tab-

32 pdf

37

- 20. Boutajangout A, Frontera J, Debure L, Vedvyas A, Faustin A, Wisniewski T. Plasma Biomarkers of Neurodegeneration and Neuroinflammation in Hospitalized COVID-19 Patients with and
- without New Neurological Symptoms. In: 2021 Alzheimer's Association International Conference.
- 36 ALZ; 2021. Accessed September 10, 2021.
 - https://alz.confex.com/alz/2021/meetingapp.cgi/Paper/57892
- 21. Virhammar J, Nääs A, Fällmar D, et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. *Eur J Neurol*. Published online December 28, 2020. doi:10.1111/ene.14703
- 12. Ameres M, Brandstetter S, Toncheva AA, et al. Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. *J Neurol.* 2020;267(12):3476.
- 23. Aamodt AH, Høgestøl EA, Popperud TH, et al. Blood neurofilament light concentration at
 admittance: a potential prognostic marker in COVID-19. *J Neurol*. Published online March 20,
 2021:1-10.
- 24. Cooper J, Stukas S, Hoiland RL, et al. Quantification of Neurological Blood-Based Biomarkers in
 Critically III Patients With Coronavirus Disease 2019. *Critical care explorations*. 2020;2(10).
 doi:10.1097/CCE.000000000000238
- 25. Frontera JA, Boutajangout A, Masurkar AV, et al. Elevation of Neurodegenerative Serum Biomarkers among Hospitalized COVID-19 Patients. doi:10.1101/2021.09.01.21262985
- 51 26. Kanberg N, Ashton NJ, Andersson L-M, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. *Neurology*. 2020;95(12):e1754-e1759.
- 27. Mariotto S, Savoldi A, Donadello K, et al. Nervous system: subclinical target of SARS-CoV-2 infection. *J Neurol Neurosurg Psychiatry*. 2020;91(9):1010-1012.
- 28. Paterson RW, Benjamin LA, Mehta PR, et al. Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. *Brain Commun.* 2021;3(3):fcab099.
- 57 29. De Lorenzo R, Loré NI, Finardi A, et al. Blood neurofilament light chain and total tau levels at 58 admission predict death in COVID-19 patients. *J Neurol*. Published online May 10, 2021. 59 doi:10.1007/s00415-021-10595-6
- 30. DeKosky ST, Kochanek PM, Valadka AB, et al. Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. *J Neurotrauma*. 2021;38(1):1-43.
- 31. Sutter R, Hert L, De Marchis GM, et al. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely III Patients with and without Coronavirus Disease 2019. *Ann Neurol.* 2021;89(3):610-616.
- 32. Nordvig AS, Fong KT, Willey JZ, et al. Potential Neurologic Manifestations of COVID-19. *Neurol Clin Pract*. 2021;11(2):e135-e146.
- 33. Belvis R. Headaches During COVID-19: My Clinical Case and Review of the Literature. Headache. 2020;60(7):1422-1426.

- 34. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-232.
- 71 35. Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 72 and implications for follow-up: results from a prospective UK cohort. *Thorax*. 2021;76(4):399-401.
- 73 36. Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences 74 of COVID-19 infections for the development of neurological disease. *Alzheimers Res Ther*. 75 2020;12(1):69.
- 76 37. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. 2021;8(5):416-427.
- 79 38. Peluso MJ, Lu S, Tang AF, et al. Markers of Immune Activation and Inflammation in Individuals 30 With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J* 31 *Infect Dis.* Published online September 27, 2021. doi:10.1093/infdis/jiab490
- 39. Kanberg N, Simrén J, Edén A, et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. *EBioMedicine*. 2021;70:103512.
- 34 40. Bozzetti S, Ferrari S, Zanzoni S, et al. Neurological symptoms and axonal damage in COVID-19 35 survivors: are there sequelae? *Immunol Res.* Published online August 7, 2021. 36 doi:10.1007/s12026-021-09220-5
- Heluso MJ, Kelly JD, Lu S, et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. *medRxiv*. Published online March 12, 2021. doi:10.1101/2021.03.11.21252311
- 42. Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. *Nat Commun.* 2020;11(1):812.
- Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol.* 2015;16(5):448-457.
- 44. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. *Nat Rev Rheumatol.* 2016;12(1):49-62.
- 45. Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor binding domain
 antibody evolution after mRNA vaccination. *Nature*. Published online October 7, 2021.
 doi:10.1038/s41586-021-04060-7
- Here 46. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. *The Lancet Haematology*. 2020;7(8):e575-e582.
- 47. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin.
 Cardiovasc Diabetol. 2021;20(1):172.
- 48. Wenzel J, Lampe J, Müller-Fielitz H, et al. The SARS-CoV-2 main protease Mpro causes

- microvascular brain pathology by cleaving NEMO in brain endothelial cells. *Nat Neurosci.*Published online October 21, 2021:1-12.
- 49. Song E, Bartley CM, Chow RD, et al. Divergent and self-reactive immune responses in the CNS
 of COVID-19 patients with neurological symptoms. *Cell Rep Med.* 2021;2(5):100288.
- 50. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. *Int J Biol Sci.* 2012;8(9):1254-1266.
- 12 51. Riazi K, Galic MA, Brent Kuzmiski J, Ho W, Sharkey KA, Pittman QJ. Microglial activation and TNFα production mediate altered CNS excitability following peripheral inflammation. *Proc Natl Acad Sci U S A*. 2008;105(44):17151-17156.
- 52. Lee W-J, Liao Y-C, Wang Y-F, Lin I-F, Wang S-J, Fuh J-L. Plasma MCP-1 and Cognitive Decline
 in Patients with Alzheimer's Disease and Mild Cognitive Impairment: A Two-year Follow-up
 Study. Sci Rep. 2018;8(1):1280.
- 18 53. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res.* 2009;29(6):313-326.
- 54. Andrews MG, Mukhtar T, Eze UC, et al. Tropism of SARS-CoV-2 for Developing Human Cortical Astrocytes. *bioRxiv*. Published online January 18, 2021. doi:10.1101/2021.01.17.427024
- 55. Crunfli F, Carregari VC, Veras FP, et al. SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability. *bioRxiv*. Published online October 13, 2020. doi:10.1101/2020.10.09.20207464
- 56. Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. *Nature*. 2021;595(7868):565-571.
- 57. Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. *JAMA Psychiatry*. 2021;78(6):682. doi:10.1001/jamapsychiatry.2021.0500
- 58. Maiese A, Manetti AC, Bosetti C, et al. SARS-CoV-2 and the brain: A review of the current knowledge on neuropathology in COVID-19. *Brain Pathol.* Published online August 13, 2021:e13013.
- 59. Xu J, Lazartigues E. Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus. *Cell Mol Neurobiol*. Published online July 4, 2020. doi:10.1007/s10571-020-00915-1
- 60. Lewis A, Frontera J, Placantonakis DG, et al. Cerebrospinal fluid in COVID-19: A systematic review of the literature. *J Neurol Sci.* 2021;421:117316.
- 61. Colombo D, Falasca L, Marchioni L, et al. Neuropathology and Inflammatory Cell Characterization in 10 Autoptic COVID-19 Brains. *Cells*. 2021;10(9). doi:10.3390/cells10092262
- Sun Y-X, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S. Inflammatory
 markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.
 Dement Geriatr Cogn Disord. 2003;16(3):136-144.
- 12 63. Abdelhak A, Hottenrott T, Morenas-Rodríguez E, et al. Glial Activation Markers in CSF and

Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? *Front Neurol.* 2019;10:280.

13

14

15

Demographic characteristics Age in years, median (IQR) 44 (37 – 57 Sex Male 55 (45.5) Female 66 (54.6) Gender 66 (54.6) Male 54 (44.6) Female 65 (53.7) Transgender 2 (1.7) Race/Ethnicity White 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) 33 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation Straight/heterosexual 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) <th>(n=52)</th> <th>No CNS PASC (n=69)</th>	(n=52)	No CNS PASC (n=69)
Sex Male 55 (45.5) Female 66 (54.6) Gender Male 54 (44.6) Female 65 (53.7) Transgender 2 (1.7) Race/Ethnicity 2 (1.7) White 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) Black/African American 3 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 35 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 3 (2.5) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 11 (9.1) Clinical characteristics 7re-existing medical conditions Autoimmune disease </td <td></td> <td></td>		
Sex Male 55 (45.5) Female 66 (54.6) Gender Male 54 (44.6) Female 65 (53.7) Transgender 2 (1.7) Race/Ethnicity White 69 (57.0) White 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) Black/African American 3 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 14 (9.1) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7) 48 (38.5 – 57)	43 (36 – 55)
Female	,	
Gender Male 54 (44.6) Female 65 (53.7) Transgender 2 (1.7) Race/Ethnicity 2 (1.7) White 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) Black/African American 3 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) <td>) 15 (28.9)</td> <td>40 (58.0)</td>) 15 (28.9)	40 (58.0)
Male 54 (44.6) Female 65 (53.7) Transgender 2 (1.7) Race/Ethnicity 69 (57.0) White 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) Black/African American 3 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 15 (12.4) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5)	37 (71.2)	29 (42.0)
Female 65 (53.7) Transgender 2 (1.7) Race/Ethnicity 69 (57.0) White 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) Black/African American 3 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lun		
Transgender	14 (26.9)	40 (58.0)
Race/Ethnicity 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) Black/African American 3 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics 9 (7.4) Cancer (treatment within 2 years prior to 3 (2.5) COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 37 (30.6) 25	36 (69.2)	29 (42.0)
White 69 (57.0) Hispanic/Latino 30 (24.8) Asian 14 (11.6) Black/African American 3 (2.5) Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to 3 (2.5) COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 37 (30.6)	2 (3.9)	0 (0)
Hispanic/Latino 30 (24.8)		
Asian		37 (56.1)
Black/African American 3 (2.5)		16 (24.2)
Pacific Islander/Native Hawaiian 1 (0.8) Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) <td></td> <td>10 (15.2)</td>		10 (15.2)
Other/unknown 4 (3.3) Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics 9 (7.4) Clinical characteristics 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6	1 (2.0)	2 (3.0)
Sexual orientation 85 (70.2) Gay/lesbian/same-gender loving 17 (14.0) Asexual 1 (0.8) Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics 9 (7.4) Clinical characteristics 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 24.9 or less 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	0 (0)	1 (1.5)
Straight/heterosexual	1 (2.0)	3 (4.3)
Gay/lesbian/same-gender loving		
Asexual 1 (0.8)		50 (84.8)
Questioning/unsure 3 (2.5) Unknown/Prefer not to answer 15 (12.4) Highest level of education Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		8 (13.6)
Unknown/Prefer not to answer	1 (2.1)	0 (0)
Highest level of education Grades 1 - 6	3 (6.3)	0 (0)
Grades 1 – 6 4 (3.3) Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	4 (7.8)	11 (15.9)
Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		
Grades 7 – 11 5 (4.1) High school/general educational development 12 (9.9) At least some college/associate's degree 11 (9.1) At least some graduate school 35 (28.9) 4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	1 (1.9)	3 (4.4)
High school/general educational development At least some college/associate's degree At least some graduate school 4 years of college/ bachelor's degree Clinical characteristics Pre-existing medical conditions Autoimmune disease Cancer (treatment within 2 years prior to COVID-19) Diabetes Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 30 or greater Characteristics of acute COVID-19 illness Asymptomatic Symptomatic/outpatient 12 (9.9) 11 (9.1) 12 (9.9) 13 (28.9) 14 (44.6) 15 (44.6) 16 (44.6) 17 (9.1) 18 (9.1) 19 (9.9) 11 (9.1) 19 (9.9) 11 (9.1)	1 (1.9)	4 (5.8)
At least some college/associate's degree 35 (28.9) At least some graduate school 35 (28.9) A years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	6 (11.5)	6 (8.7)
At least some graduate school 4 years of college/ bachelor's degree Clinical characteristics Pre-existing medical conditions Autoimmune disease Cancer (treatment within 2 years prior to COVID-19) Diabetes Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 30 or greater Characteristics of acute COVID-19 illness Asymptomatic Symptomatic/outpatient 35 (28.9) 54 (44.6) 36 (28.9) 54 (44.6) 37 (3.6) 3 (2.5) 3 (2.5) 3 (2.5) 3 (2.5) 4 (11.6) 3 (2.5) 4 (11.6) 3 (2.5) 4 (11.6) 5 (4.1) 8 (1.1)		4 (5.8)
4 years of college/ bachelor's degree 54 (44.6) Clinical characteristics Pre-existing medical conditions Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		20 (29.0)
Clinical characteristics Pre-existing medical conditions 9 (7.4) Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		32 (46.4)
Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		
Autoimmune disease 9 (7.4) Cancer (treatment within 2 years prior to COVID-19) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		
Cancer (treatment within 2 years prior to COVID-19) 3 (2.5) Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	6 (11.5)	3 (4.4)
Diabetes 14 (11.6) Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	2 (3.9)	1 (1.5)
Lung problems 23 (19.0) BMI category 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	7 (13.7)	7 (10.1)
BMI category 42 (34.7) 24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		11 (16.2)
24.9 or less 42 (34.7) 25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)	(_0,	()
25 to 29.9 37 (30.6) 30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)) 15 (28.9)	27 (39.1)
30 or greater 41 (33.9) Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		29 (42.0)
Characteristics of acute COVID-19 illness Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		12 (17.4)
Asymptomatic 5 (4.1) Symptomatic/outpatient 89 (73.6)		
Symptomatic/outpatient 89 (73.6)	1 (1.9)	4 (5.8)
, ,		51 (73.9)
Symptomatic/hospitalized 27 (22.3)		14 (20.3)
	13 (23.0)	14 (20.3)
Characteristics of late recovery		
Total PASC symptoms, mean (range) median (IQR) $3.3 (0-18) (0-6)$, , ,	0.64 (0 – 7) 0 (0 – 1)

Trouble concentrating, trouble with your thinking, or trouble with your memory	42 (34.7)	42 (80.8)	0 (0)
Headache	18 (14.9)	18 (34.6)	0 (0)
Trouble with vision, for example, double vision, blurry vision, or other visual issues	13 (10.7)	13 (25.0)	0 (0)
Dizziness	18 (14.9)	18 (34.6)	0 (0)
Trouble with balance or feeling unsteady	13 (10.7)	13 (25.0)	0 (0)
Trouble with taste or smell	27 (22.3)	20 (38.5)	7 (10.1)
Smelling an odor that is not actually there	8 (6.6)	7 (13.5)	1 (1.5)
Numbness, tingling, or 'pins and needles' in your arms or legs	17 (14.1)	16 (30.8)	1 (1.5)
Feeling feverish	2 (1.7)	2 (3.9)	0 (0)
Measured a temperature of >100.4F or 38C	2 (1.7)	2 (3.9)	0 (0)
Chills, feeling unusually cold	2 (1.7)	2 (3.9)	0 (0)
Feeling tired or having low energy	41 (33.9)	37 (71.2)	4 (5.8)
Cough	13 (10.7)	11 (21.2)	2 (2.9)
Shortness of breath	28 (23.1)	25 (48.1)	3 (4.4)
Chest Pain	18 (14.9)	13 (25.0)	5 (7.3)
Feeling your heart pound or race	15 (12.4)	13 (25.0)	2 (2.9)
Runny nose or congestion	14 (11.6)	9 (17.3)	5 (7.3)
Sore throat	7 (5.8)	6 (11.5)	1 (1.5)
Muscle aches	20 (16.5)	19 (36.5)	1 (1.5)
Loss of appetite	12 (9.9)	11 (21.2)	1 (1.5)
Nausea, gas, or indigestion	17 (14.1)	15 (28.9)	2 (2.9)
Vomiting	1 (0.8)	1 (1.9)	0 (0)
Stomach pain	6 (5.0)	3 (5.8)	3 (4.4)
Constipation	3 (2.5)	3 (5.8)	0 (0)
Diarrhea or loose bowels	9 (7.4)	8 (15.4)	1 (1.5)
New spots or a rash on your skin	10 (8.3)	9 (17.3)	1 (1.5)
Fainting spells	0 (0)	0 (0)	0 (0)
Pain in your arms, legs or joints such as knees and hips	9 (7.4)	9 (17.3)	0 (0)

Back pain	7 (5.8)	6 (11.5)	1 (1.5)
Trouble sleeping	32 (26.5)	26 (500)	6 (8.7)
Menstrual cramps or other problems with your periods	2 (1.7)	2 (3.9)	0 (0)
Pain or problems during sexual intercourse	0 (0)	0 (0)	0 (0)

All values listed are number (percentage) unless otherwise specified. IQR = interquartile range.




Figure 1. Cross-sectional measurements and longitudinal trends in biomarker levels among those with and without CNS PASC. P-values reflect group comparisons during early and late recovery, as well as comparison of change over time between groups. GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor alpha; IL-10, interleukin-10; IFN-gamma, interferon-gamma; MCP-1, monocyte chemoattractant protein 1; IP-10, interferon-gamma induced protein 10; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IgG immunoglobulin G. Early recovery represents a median of 52 days post-SARS-CoV-2 symptom onset (or positive PCR); late recovery represents a median of 123 days post-SARS-COV-2 symptom onset (or positive PCR).




Figure 2. Relationships between biomarkers of neurologic injury and systemic inflammation in the full cohort. Data reflect non-parametric correlations between markers at early and late recovery timepoints. GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor alpha; IL-10, interleukin-10; IFN-gamma, interferon-gamma; MCP-1, monocyte chemoattractant protein 1; IP-10, interferon-gamma induced protein 10; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IgG immunoglobulin G. Early recovery represents a median of 52 days post-SARS-CoV-2 symptom onset (or positive PCR); late recovery represents a median of 123 days post-SARS-COV-2 symptom onset (or positive PCR).